Becton, Dickinson and Company (BDX) Issues FY18 Earnings Guidance
Becton, Dickinson and Company (NYSE:BDX) updated its FY18 earnings guidance on Thursday. The company provided EPS guidance of 10.55-10.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.41.
A number of brokerages have recently commented on BDX. Wells Fargo & Company reaffirmed a positive rating and set a $235.00 price objective (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank Of Canada reissued a hold rating and issued a $210.00 target price on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Becton, Dickinson and from a sell rating to a hold rating in a research note on Friday, October 20th. Bank of America Corporation reissued a buy rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Finally, Piper Jaffray Companies reissued a buy rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $205.79.
Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.12 EPS.
In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 in the last 90 days. Corporate insiders own 1.40% of the company’s stock.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.